Skip to main content
Prelude Therapeutics loss narrows to $12.5 million
Image for illustrative purposes only. Not a real photo.

Prelude Therapeutics loss narrows to $12.5 million

By

Key points

  • Prelude Therapeutics (NASDAQ:PRLD) reported a third-quarter 2026 net loss of $12.544 million, narrowing from $19.725 million a year earlier.
  • Revenue declined to $5.647 million from $6.5 million, while cash, restricted cash and marketable securities totalled $142.7 million.
  • Prelude began Phase 1 enrollment for breast cancer candidate PRT13722 and expects initial proof-of-concept data in the second half of 2027.

Prelude Therapeutics (NASDAQ:PRLD) reported a third-quarter 2026 net loss of $12.544 million, compared with $19.725 million a year earlier, as research and development expenses declined.

Revenue fell 13.1% to $5.647 million from $6.5 million, while loss per share narrowed to $0.12 from $0.26 and research and development expenses decreased to $14.830 million from $21.708 million.

General and administrative expenses declined slightly to $5.082 million from $5.210 million, while cash, cash equivalents, restricted cash and marketable securities reached $142.7 million at September 30, with funding expected into the second quarter of 2028.

The company began Phase 1 enrollment for PRT13722, an oral KAT6A degrader being developed for hormone receptor-positive, HER2-negative breast cancer, and signed an October collaboration with Lilly to evaluate combinations with abemaciclib and imlunestrant.

Prelude also continued Phase 1 enrollment for PRT12396, a mutant-selective JAK2V617F inhibitor targeting polycythemia vera and myelofibrosis, while selecting a development candidate for its mCALR-targeted degrader antibody conjugate program.


Frequently asked questions